A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma.

Inherited genetic susceptibility to multiple myeloma. Leukemia (2013) 1.04

Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes. Oncotarget (2016) 0.79

Association of interferon regulatory factor 4 gene polymorphisms rs12203592 and rs872071 with skin cancer and haematological malignancies susceptibility: a meta-analysis of 19 case-control studies. BMC Cancer (2014) 0.76

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma. Arch Immunol Ther Exp (Warsz) (2017) 0.75

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93

Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med (2008) 5.48

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 4.94

Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet (2009) 4.47

A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2008) 4.37

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol (2013) 3.75

The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc (2012) 3.45

Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol (2004) 2.91

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood (2008) 2.88

Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. Br J Haematol (2014) 2.80

Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol (2005) 2.62

IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14). Br J Haematol (2008) 2.54

Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47

Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood (2006) 2.43

Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood (2007) 2.38

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38

Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Clin Oncol (R Coll Radiol) (2004) 2.35

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood (2010) 2.25

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol (2005) 2.20

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood (2010) 2.16

The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood (2008) 2.16

Optimizing protein stability in vivo. Mol Cell (2009) 2.15

Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol (2011) 2.14

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood (2010) 2.09

gammaH2AX foci form preferentially in euchromatin after ionising-radiation. PLoS One (2007) 2.07

Burkitt's lymphoma. Lancet (2012) 2.02

MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood (2008) 1.98

Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood (2002) 1.95

Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood (2007) 1.93

CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol (2014) 1.92

Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol (2005) 1.83

A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood (2008) 1.80

BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med (2013) 1.79

Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res (2008) 1.77

The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma (2009) 1.77

Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76

Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol (2003) 1.71

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol (2011) 1.71

The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res (2007) 1.70

Contribution of problem drug users' deaths to excess mortality in Scotland: secondary analysis of cohort study. BMJ (2008) 1.69

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood (2010) 1.67

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol (2011) 1.66

Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J (2011) 1.65

Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes. Am Heart J (2012) 1.65

A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood (2004) 1.65

Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J Natl Cancer Inst (2004) 1.64

Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64

Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkin's lymphoma. Haematologica (2006) 1.64

Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology (2014) 1.64

MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukemia. Blood (2010) 1.62

The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res (2011) 1.61

The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire. Blood (2010) 1.61

Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care (2011) 1.60

Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood (2003) 1.60

High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma (2010) 1.58

Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis. Cancer Res (2005) 1.57

Evidence based medicine inevitably increases testosterone prescribing. BMJ (2012) 1.54

Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res (2003) 1.53

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood (2002) 1.51

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood (2011) 1.50

The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma (2006) 1.49

Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol (2009) 1.48

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood (2008) 1.45

Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. Blood (2013) 1.45

Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res (2011) 1.44

Diagnosis and management of acute graft-versus-host disease. Br J Haematol (2012) 1.43

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood (2004) 1.43

Summary of the recommendations on sexual dysfunctions in men. J Sex Med (2010) 1.42

Less than half of patients aged 65 years or under with myeloma proceed to transplantation: results of a two region population-based survey. Br J Haematol (2005) 1.41

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood (2004) 1.40

CEMO in a UK stallion. Vet Rec (2002) 1.39

Self-expanding stent implantation in arterial duct during hybrid palliation of hypoplastic left heart syndrome: midterm experience with a specially designed stent. EuroIntervention (2015) 1.39

Giving up smoking. Hosp Med (2004) 1.39

Believe-it then PROVE-IT. Int J Clin Pract (2004) 1.39

Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res (2010) 1.39

Post-transcriptional exon shuffling events in humans can be evolutionarily conserved and abundant. Genome Res (2011) 1.38